Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

In addition to the added convenience of oral dosing, HIF-PH inhibitors could also avoid some of the side effects linked to ESAs, including a higher risk of blood clots and tumours. They also don't ...

The decision makes Evrenzo (roxadustat) the first oral HIF-PH inhibitor to be cleared for use in the EU, ahead of rival candidates daprodustat from GlaxoSmithKline and Akebia Therapeutics' vadadustat.

e-Fuels leader approved for Tier II design pathway under California LCFS HOUSTON, March 11, 2025 /PRNewswire/ -- HIF Global, the leader in highly innovative fuels, is proud to announce that it has ...